IL17A and tuberculosis: In a previous Korean nationwide nested case-control analysis that was conducted to assess the risk of cancer, TB, and serious infections in patients with AS, PsA, and psoriasis treated with IL-17 and TNF-α inhibitors, it was shown that IL-17 inhibitors may offer an advantage in terms of TB risk [19].